Imugene Ltd’s (ASX: IMU, OTC: IUGNF) Phase 1 CHECKVacc trial in adults with triple-negative breast cancer was detailed in a publication for the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The abstract, titled “Phase 1 study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple-negative breast cancer,” presents the results obtained so far from the trial.
The lead author and principal investigator of the trial is Dr. Yuan Yuan MD, PhD of City of Hope National Medical Center, Duarte, California.
Imugene is a clinical-stage immuno-oncology company developing a range of new and innovative immunotherapies with the goal of activating the immune system of cancer patients to treat and eradicate tumors.
The Company’s platform technologies seek to harness the body’s immune system against tumors, potentially achieving a similar or superior effect to synthetically produced monoclonal antibodies and other immunotherapies.
Imugene’s product portfolio includes several B-cell immunotherapeutic vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with reference drugs and emerging immunotherapies such as CAR-Ts for solid tumors .
The company is supported by a leading team of international cancer experts with extensive experience in the development of novel cancer therapies, many of which have been approved for sale and commercialization in global markets.